Gilead Sciences: Hep-C Prescriptions Continue to Fall

RBC’s Michael Yee and John Chung have the latest prescription data from Gilead Sciences’ (GILD) hepatitis-c drugs: Bloomberg Harvoni TRx 9392 (-2% wk/wk), NRx 3551 (-3% wk/wk); Harvoni+Sovaldi TRx 11189 (-2% wk/wk), NRx 4104 (-3% wk/wk) (ending 05/15/15). GILD’s weekly Hep C scripts are tracking towards $3.1-3.2B USA (vs cons $3.1B USA) for Q 2:15, [...]